– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Compan

Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the unde

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin exec

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 20

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold an

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in

ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growt

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Co

ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.21 per share which beat the anal

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ®

ANI Pharmaceuticals is rated Buy at ~$80, with a 12-month fair value set at $95, as the current valu

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings be

PRINCETON, N. J. , July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI o

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at e

Bessemer Group Inc. lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 52.

Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) wi

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. R

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enric

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its flu

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its flu

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced positive topline data f

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and mainta

ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $8.83-$9.34 to $9.19-$9.69 vs

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.05 per share which beat the anal

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced the launch of Pimozide

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final ap

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the resu

ANI Pharma beats Q4 estimates, swings to profit, and sees over $1 billion in 2026 sales as Rare Dise

ANI Pharmaceuticals (NASDAQ:ANIP) is looking for FY2026 Adj EPS of $8.83-$9.34 vs $8.58 analyst esti

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.33 per share which beat the anal

CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developi